RxDoctor Payments Data

Cassandra Kelley

Family · Montgomery, ALNPI 1952956567

Payments from drug & device makers

$1,854in general payments, 2019–2025

Across 55 payments — averaging $33.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$404
  • AstraZeneca$312
  • AbbVie$174
  • Edwards Lifesciences$144
  • Boehringer Ingelheim$131
  • Amgen$127
  • plus $562 from 14 others

What the payments were for

  • Food & beverage$1,854100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,854 in reported general payments places this provider in the 75th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$25,608
Medicare patients
349
Services billed
577

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban50$55,042
Repatha SureclickEvolocumab29$21,968
XareltoRivaroxaban18$13,465
Ranolazine ErRanolazine25$2,103
Diltiazem 24hr Er (Cd)Diltiazem Hcl31$656
Metoprolol Succinate28$483
Losartan Potassium29$380
Atorvastatin Calcium29$350
Nitroglycerin36$333
Carvedilol31$257
Potassium Chloride11$256
Ramipril19$255
ClopidogrelClopidogrel Bisulfate18$180
Furosemide27$143
Spironolactone11$135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$96$55,04250 claims
Johnson & JohnsonXarelto$12$13,46518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,415 family providers in Alabama.

Other family in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →